CalciMedica Q3 net loss narrows 78% to $1.7 million
CALC•CalciMedica’s third-quarter 2026 net loss narrowed 78% year over year to $1.7 million. It had $13.8 million in cash, cash equivalents and short-term investments at September 30, expected to fund operations into the second half of 2027.
1. Quarterly results and outlook
CalciMedica’s third-quarter 2026 net loss narrowed 78% year over year to $1.7 million, while total other income was $3.1 million, compared with a $2.2 million expense a year earlier. Cash, cash equivalents and short-term investments totaled $13.8 million at September 30, which the company expects to fund operations into the second half of 2027. Auxora pulmonary hypertension trial data and a CM5480 investigational new drug submission are both expected in mid-2027.
